Finding anti-inflammatory drugs with higher specificity and fewer side effects than steroids is of considerable importance for clinicians in many fields of medicine. In May
Weitz-Schmidt et al found that the anti-inflammatory properties of statins is a function of their ability to prevent the binding between β2 integrin leukocyte function antigen-1 (LFA-1) and ICAM-1 via a novel allostearic site within LFA-1. This effect stops the recruitment of leukocytes to sites of inflammation and is unrelated to the statins ability to inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA) — the mechanism by which statins reduce cholesterol levels. They subsequently developed the molecule LFA703 with enhanced binding affinity for the LFA-1, but with reduced activity against HMG-CoA. LFA703 ...